IO Nation: The Rise of Immuno-Oncology

Author(s): Scott Palmer, Georgiana L. Kuhlmann, Kristin Pothier

Journal Name: Current Pharmacogenomics and Personalized Medicine
Formerly Current Pharmacogenomics

Volume 12 , Issue 3 , 2014

Become EABM
Become Reviewer
Call for Editor


The field of immuno-oncology (IO) is rapidly expanding, generating enormous interest on the part of drug developers and giving new hope to patients and physicians. Attempts to harness the immune system to fight cancer date back to the 19th century; however, it is only in recent years that immunotherapies have entered mainstream oncology and have shown promise across a broad range of tumor types. New therapeutic combinations are emerging, with companies pairing two immunotherapies, an immunotherapy and a molecularly targeted therapy, or an immunotherapy plus traditional chemotherapy in order to more effectively fight cancer. Some immunotherapies are also pairing with companion diagnostics in order to maximize efficacy in patient populations. All of these developments come with their own unique challenges that drug developers will need to confront. This Perspective article reviews developments in the IO field and highlights key challenges in successfully commercializing an IO therapy.

Keywords: Commercialization, companion diagnostics, immuno-oncology, oncology, precision medicine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 16 March, 2015
Page: [176 - 181]
Pages: 6
DOI: 10.2174/1875692113666150115222451
Price: $25

Article Metrics

PDF: 32